Illuminating cancer therapy via cryptic antigens.

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-07-24 DOI:10.1016/j.trecan.2025.07.003

Jiling Feng, Yu Zeng, Shengli Li

引用次数: 0

Abstract

A recent study in Science by Ely et al. identifies immunogenic, cancer-restricted noncanonical HLA-I-bound peptides (ncHLAp) in pancreatic cancer. Using a translation-informed filtering strategy, the study uncovers cryptic antigens derived from unannotated ORFs and validate antigen-specific T cell receptors (TCRs) capable of targeting pancreatic ductal adenocarcinoma (PDAC) in preclinical models, offering new avenues for immunotherapy.

查看原文本刊更多论文

通过隐藏抗原照亮癌症治疗。

Ely等人最近在《科学》杂志上发表的一项研究发现，胰腺癌中存在免疫原性、癌症限制性的非规范hla - i结合肽（ncHLAp）。利用翻译信息过滤策略，该研究揭示了来自未注释orf的隐性抗原，并在临床前模型中验证了抗原特异性T细胞受体（TCRs）能够靶向胰腺导管腺癌（PDAC），为免疫治疗提供了新的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.